This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced it will release financial results for the fourth quarter and full year ended December 31, 2010 after market close on Thursday, March 3, 2011 at 4:30 p.m. ET (1:30 p.m. PT) and hold a conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for the fourth quarter and full year ended December 31, 2010.
The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.
To participate, please dial 800-299-0433 (USA) or 617-801-9712 (International); participant passcode: 81672996. To access the live webcast please visit the Investor Relations website at ir.zogenix.com.
A replay of the conference call will be available beginning March 03, 2011 at 8:30 p.m. ET (5:30 p.m. PT) and ending on April 03, 2011 by dialing 888-286-8010 (USA) or 617-801-6888 (International); passcode: 49748006. A replay of the webcast will also be available on the Investor Relations website for one month, through April 17, 2011.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL
® DosePro™ (
sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, ZX002, is a novel, oral, single-entity controlled-release formulation of
hydrocodone currently in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy.
For additional information, please visit
Sara Pellegrino | The Ruth Group
646.536.7002 | email@example.com
Jason Rando | The Ruth Group
646.536.7025 | firstname.lastname@example.org